Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 112 of the 113 references it cites were found in a registry or an index; 50 of the 105 sources its claims cite were checked for support.

Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes

Open access

Abstract

The discovery of long-acting incretin receptor agonists represents a major stride forward in tackling the dual epidemic of obesity and diabetes. Here we outline the evolution of incretin-based pharmacotherapy, from exendin-4 to the discovery of the multi-incretin hormone receptor agonists that look set to be our next step toward curing diabetes and obesity. We discuss the multiagonists currently in clinical trials and the improvement in efficacy each new generation of these drugs bring. The success of these agents in preclinical models and clinical trials suggests a promising future for multiagonists in the treatment of metabolic diseases, with the most recent glucose-dependent insulinotropic peptide receptor:glucagon-like peptide 1 receptor:glucagon receptor (GIPR:GLP-1R:GCGR) triagonists rivaling the efficacy of bariatric surgery. However, further research is needed to fully understand how these therapies exert their effect on body weight and in the last section we cover open questions about the potential mechanisms of multiagonist drugs, and the understanding of how gut-brain communication can be leveraged to achieve sustained body weight loss without adverse effects.

Overview

CoChat Summary

TL;DR

This review traces the evolution from GLP-1 monoagonists to dual and triple incretin co-agonists as increasingly effective therapies for obesity and diabetes. It argues that the newest triagonists, especially retatrutide, approach bariatric-surgery-level weight loss, but key mechanisms and long-term effects remain unresolved.

Key findings

  • Exenatide, the first FDA-approved incretin agonist for diabetes, reduced HbA1c by −0.8% at 5 μg and −1.0% at 10 μg after 30 weeks, and both doses reduced body weight.
  • Once-weekly semaglutide 2.4 mg produced −14.9% body-weight reduction in adults with obesity, with improved glucose homeostasis and reduced cardiovascular risk.
  • In DIO mice, a balanced GLP-1/glucagon dual agonist produced about 10% greater body-weight reduction than a GLP-1R-favoring version, with similar effects on glucose tolerance.
  • Retatrutide showed very large effects: in phase 2 obesity data, 60%, 75%, and 83% of participants on 4, 8, and 12 mg lost at least 15% of body weight by 48 weeks, and the 12 mg dose produced a mean 24.2% weight reduction; in diabetes, 72% of participants with prediabetes returned to normoglycemia vs 22% on placebo.

Methods

  • Narrative review of previously published preclinical and clinical studies on incretin monoagonists, dual agonists, and triagonists; no new human or animal experiments were conducted by the authors.
  • Synthesizes evidence from DIO mouse studies and human clinical trials, including phase 1, phase 2, and phase 3 studies of agents such as cotadutide, survodutide, mazdutide, tirzepatide, HM15211, and retatrutide.
  • Main analysis is qualitative comparison of efficacy, safety/tolerability, and proposed mechanisms across drug classes.

Limitations

  • The paper explicitly says that the precise mechanisms driving body-weight reduction remain obscure, especially for the enhanced effects of multiagonism.
  • It also states that further research is needed to understand which brain regions, cell types, and downstream circuits mediate incretin effects, and to clarify long-term weight maintenance and lean-mass preservation.
  • Evident from the text: this is a review, so its conclusions depend on previously published studies rather than original data collection; the paper says this directly by noting it contains no new studies.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1007/s13300-024-01566-x

Cites

112 of 112 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Synergies in mechanisms that regulate body weight and glucose metabolism by incretin agonism across tissues in humans [22, 23, 106]. Different incretin agonists exert complementary effects on key peripheral organs and the brain to both directly and indirectly affect energy and glucose. GIP glucose-dependent insulinotropic polypeptide, GLP-1 glucagon-like protein 1. Created by BioRender.com
Fig. 1 Synergies in mechanisms that regulate body weight and glucose metabolism by incretin agonism across tissues in humans [22, 23, 106]. Different incretin agonists exert complementary effects on key peripheral organs and the brain to both directly and indirectly affect energy and glucose. GIP glucose-dependent insulinotropic polypeptide, GLP-1 glucagon-like protein 1. Created by BioRender.comCC BY-NC · PubMed Central
Fig. 2 A The amino acid sequence of a GLP-1R/GCGR dual agonist MK1462 [116], B the amino acid sequence of the GLP-1R/GIPR dual agonist tirzepatide [117], and C the amino acid sequence of a triagonist [99]. These multiagonists are an assemblage of parts from each incretin and incorporated lessons learned from prior incretin mimetics: Aib substitute to prevent degradation by DPP4, acylation from liraglutide or semaglutide to increase solubility, and the CEX tail from exendin-4. GCGR glucagon receptor, GIPR GIP receptor, GLP-1R GLP-1 receptor, Aib 2-aminoisobutyric acid, DPP4 dipeptidyl peptidase 4, CEX C-terminal extension
Fig. 2 A The amino acid sequence of a GLP-1R/GCGR dual agonist MK1462 [116], B the amino acid sequence of the GLP-1R/GIPR dual agonist tirzepatide [117], and C the amino acid sequence of a triagonist [99]. These multiagonists are an assemblage of parts from each incretin and incorporated lessons learned from prior incretin mimetics: Aib substitute to prevent degradation by DPP4, acylation from liraglutide or semaglutide to increase solubility, and the CEX tail from exendin-4. GCGR glucagon receptor, GIPR GIP receptor, GLP-1R GLP-1 receptor, Aib 2-aminoisobutyric acid, DPP4 dipeptidyl peptidase 4, CEX C-terminal extensionCC BY-NC · PubMed Central

Verification

Claims the paper makes

34 Valid · 0 Not valid · 35 Not checked · 11 Own results and interpretations

36 more claims · 15 with their cited sources checked

Create a free account to see all 80 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 34
  • Probably not a substantial claim. 6
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Citations

Cites

  • Positional cloning of the mouse obese gene and its human homologue

    Zhang, Y., Proenca, R., Maffei, M., Barone, M., Leopold, L., & Friedman, J. M. (1994) · Nature · doi:10.1038/372425a0 · Cited by 13,419 · cited 1×

    “This new paradigm began with the discovery of leptin, by Jeff Friedman and others in 1994, the first hormone whose primary function is the regulation of body weight, by signaling from the adipose tissue to pro-opiomelanocortin (POMC) neurons [6] in the hypothalamus to reduce food intake.”
    Method
  • Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019

    Murray, C. J. L., Aravkin, A. Y., Zheng, P., Abbafati, C., Abbas, K. M., Abbasi-Kangevari, M., Abd-Allah, F., Abdelalim, A., Abdollahi, M., Abdollahpour, I., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30752-2 · Cited by 9,854 · cited 1×

    “The global prevalence of obesity and diabetes continues to surge, contributing significantly to morbidity and mortality through diseases like heart disease and cancer [1].”
    Background
  • Ghrelin is a growth-hormone-releasing acylated peptide from stomach

    Kojima, M., Hosoda, H., Date, Y., Nakazato, M., Matsuo, H., & Kangawa, K. (1999) · Nature · doi:10.1038/45230 · Cited by 8,479 · cited 1×

    “This was followed by the discovery of an opposing hormone, ghrelin, which facilitates signaling from the gut and acts on agouti-related peptide (AgRP) neurons in the hypothalamus to increase food intake [7, 8].”
    Background
  • Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

    Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 1×

    “Created by BioRender.com liraglutide and semaglutide, but not exenatide, had a lower risk of non-fatal myocardial infarction and stroke [66, 70, 71] and another GLP-1R agonist, dulaglutide, reduced major adverse cardiovascular events [72].”
    Background
  • Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

    Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 2×

    “A once-weekly injection of 2.4 mg of semaglutide resulted in a remarkable reduction in body weight by − 14.9% in adults with obesity, along with substantial improvements in glucose homeostasis and reduced risk of cardiovascular events [66, 67].”
    BackgroundInfluential
  • Once-Weekly Semaglutide in Adults with Overweight or Obesity

    Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205 · cited 1×

    “A once-weekly injection of 2.4 mg of semaglutide resulted in a remarkable reduction in body weight by − 14.9% in adults with obesity, along with substantial improvements in glucose homeostasis and reduced risk of cardiovascular events [66, 67].”
    BackgroundInfluential
  • Genetic studies of body mass index yield new insights for obesity biology

    Study, T. L. C., Locke, A. E., The ADIPOGen Consortium, The AGEN-BMI Working Group, The CARDIOGRAMplusC4D Consortium, The CKDGen Consortium, The, G. L. G. C., The, I. C. B. P., The MAGIC Investigators, The MuTHER Consortium, et al. (2015) · Nature · doi:10.1038/nature14177 · Cited by 4,534 · cited 1×

    “…of leptin has revolved around the idea that BMI has a genetic basis, with approximately 40–70% of the variation in BMI in the population being attributable to heritable factors [9], and that the majority of genetic variation associated with BMI is in the central nervous sys-tem (CNS) [10].”
    Background
  • Ghrelin induces adiposity in rodents

    Tschöp, M., Smiley, D. L., & Heiman, M. L. (2000) · Nature · doi:10.1038/35038090 · Cited by 3,949 · cited 1×

    “This was followed by the discovery of an opposing hormone, ghrelin, which facilitates signaling from the gut and acts on agouti-related peptide (AgRP) neurons in the hypothalamus to increase food intake [7, 8].”
    BackgroundSelf-citation
  • Tirzepatide Once Weekly for the Treatment of Obesity

    Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · cited 1×

    “In its phase 3 trial in adults with obesity, the highest dose of 15 mg once weekly produced an average reduction in body weight of 22.5% after 72 weeks of treatment [91], and a 15.7% reduction in body weight in patients with obesity and diabetes [92].”
    BackgroundInfluential
  • Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

    Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236 · cited 1×

    “…patients with overweight or obesity and established cardiovascular disease, but no diabetes, that were treated with semaglutide had a significantly lower composite of cardiovascular events (death from cardiovascular causes, nonfatal myocardial infarction, and nonfatal stroke) than placebo [73].”
    Background

Show all 113 references

Research works printed but not linked: 2

  1. IDF Diabetes Atlas 10th edition. International Diabetes Federation; 2021. (IDF Diabetes Atlas). Report no. 10. https://diabetesatlas.org/atlas/tenth-edition/.
  2. Ji L, Gao L, Jiang H, et al. Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: a randomised, placebo-controlled, multiple-ascending-dose phase 1b trial. EClinicalMedicine. 2022;54:101691. · DOI · Paper page

Cited by

See all 61

Metadata

Authors
Gutgesell, R. M., Nogueiras, R., Tschöp, M. H., & Müller, T. D.
Affiliations
  • Helmholtz Munich (DE)
  • Universidade de Santiago de Compostela (ES)
Corresponding author
Müller, Timo D.
Venue
Diabetes Therapy
Published
2024-04-04
Volume
15
Issue
5
Pages
1069-1084
ISSN
  • 1869-6953 (ISSN-L)
  • 1869-6961
OpenAlex
W4393932284
Cited by
61
References
113
Citations by year
2026: 22 · 2025: 33 · 2024: 6
FWCI
3.56
Type
journal article
Language
en
Open access
Licence
Locations
  • Diabetes Therapy (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • PuSH - Publication Server of Helmholtz Zentrum München (submittedVersion, cc-by-nc)
  • mediaTUM (Technical University of Munich) (submittedVersion)
Funders
European Research Council (ERC-CoG Trusted no.101044)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
Keywords
exendin-4, obesity, type 2 diabetes, glucose-dependent insulinotropic polypeptide, GLP-1 receptor, glucagon receptor, weight loss, gut-brain signaling, bariatric surgery alternatives

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes. https://app.cochat.ai/papers/10.1007/s13300-024-01566-x
The paper
Gutgesell, R. M., Nogueiras, R., Tschöp, M. H., & Müller, T. D. (2024). Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes. Diabetes Therapy. https://doi.org/10.1007/s13300-024-01566-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.